文献速递泌尿男性生殖肿瘤

前列腺癌患者年龄相关性黄斑变性风险:全国性人群队列研究

Risk of age-related macular degeneration in patients with prostate cancer: a nationwide, population-based cohort study.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究基于台湾纵向健康保险数据库1999-2010年数据,纳入22 084例新诊断前列腺癌患者并按1:1匹配对照,评估年龄相关性黄斑变性(AMD)发生风险。结果显示前列腺癌队列AMD风险高于倾向评分匹配的非前列腺癌队列(调整HR 1.25,95%CI 1.12-1.39);接受注射激素治疗的前列腺癌患者AMD风险低于未接受者(调整HR 0.56,95%CI 0.41-0.76)。

要点

  • 前列腺癌患者AMD风险较匹配对照升高(调整HR 1.25,95%CI 1.12-1.39)。
  • 前列腺癌接受注射激素治疗者AMD风险低于未接受者(调整HR 0.56,95%CI 0.41-0.76)。
  • 前列腺癌队列平均年龄73.9岁,约85.9%患者年龄>65岁。

核心结论

  • 前列腺癌与AMD风险升高相关。
  • 接受注射剂型雄激素剥夺治疗的前列腺癌患者AMD风险低于未接受该治疗者。

研究设计与样本

  • 全国性、人群为基础的队列研究,数据来自台湾纵向健康保险数据库1999-2010年。
  • 前列腺癌队列含22 084例年龄≥18岁首次诊断前列腺癌患者,对照按年龄、职业、城市化水平1:1匹配。

主要发现

  • AMD患者中,匹配的前列腺癌队列与非前列腺癌队列平均随访期分别为4.69(2.90)年和5.51(2.82)年。
  • 前列腺癌队列平均年龄73.9岁,非前列腺癌队列73.2岁,约85.9%患者年龄>65岁。
  • 前列腺癌队列AMD风险高于倾向评分匹配的非前列腺癌队列,调整HR 1.25(95%CI 1.12-1.39)。
  • 接受注射激素治疗的前列腺癌队列AMD风险低于未接受注射激素治疗的前列腺癌队列,调整HR 0.56(95%CI 0.41-0.76)。

关键数值与推荐

  • 主要结局为AMD发生率,采用Kaplan-Meier生存分析和比例风险模型评估。

临床怎么用

  • 前列腺癌患者AMD风险升高,接受注射激素治疗者AMD风险较低。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PC) can be related to increased systemic oxidative stress and dihydrotestosterone level, which are also reported to be involved in the pathogenesis of age-related macular degeneration (AMD). We conducted a cohort study to determine whether patients with PC have an increased risk of AMD. PATIENTS AND METHODS: Data were collected from the Taiwan Longitudinal Health Insurance Database for the 1999-2010 period. The study PC cohort comprised 22 084 patients aged ≥18 years with a first diagnosis of PC. The comparison cohort consisted of age-, occupation-, and urbanization level-matched patients at a ratio of 1 : 1. The primary outcome was the incidence of AMD, which was evaluated using Kaplan-Meier survival analysis and proportional hazards modeling. RESULTS: The mean follow-up periods (standard deviation) for the patients with AMD in the age-, occupation-, and urbanization level-matched PC cohort and non-PC cohorts were 4.69 (2.90) and 5.51 (2.82) years. The mean age of the PC cohort was 73.9 years and that of the non-PC cohort was 73.2 years, with approximately 85.9% of the patients aged >65 years. The PC cohort had a higher risk of AMD than did the propensity score-matched non-PC cohort with an adjusted hazard ratio of 1.25 (95% confidence interval, 1.12-1.39). Compared with PC cohort receiving no injection hormone therapy, the PC cohort receiving injection hormone therapy had a lower risk of AMD (adjusted hazard ratio, 0.56; 95% confidence interval, 0.41-0.76). CONCLUSION: PC is associated with an increased risk of AMD. Patients with PC receiving injected form of androgen deprivation therapy had a lower risk of AMD than patients with PC not receiving injected form of androgen-deprivation therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lin SY, Lin CL, Chang CH, et al. Risk of age-related macular degeneration in patients with prostate cancer: a nationwide, population-based cohort study. Ann Oncol. 2017. PMID: 28961846. doi:10.1093/annonc/mdx402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。